

Transformations of Some Sesquiterpene Lactones by Filamentous Fungi. Cytotoxic Evaluations.

Arturo Cano-Flores,^a and Guillermo Delgado^{*,b}

^a Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México. Av. Guelatao No 66 (Eje 7 Oriente). Col Ejército de Oriente, Iztapalapa 09230. Ciudad de México, México

^b Instituto de Química, Universidad Nacional Autónoma de México. Ciudad Universitaria, Circuito Exterior, Coyoacán 04510. Ciudad de México, México, Email: delgado@unam.mx

Biotransformation is an economically and ecologically viable technology which has been used to modify the structures of many classes of biologically active products. Some fungi may be useful for the biotransformation of sesquiterpene lactones (SLs), leading to unusual structural changes that modify their biological activities, and other transformations mimic their biosynthetic pathways, generating evidences for the proposed biogenesis. Eight filamentous fungi were screened for their ability to transform different SLs (**1-9**), and microbial reactions yielded compounds **11 -- 18**, which in turn have been isolated as natural products, thus mimicking their biosynthesis. Their structures were identified based on NMR and MS spectroscopic analyses. The cytotoxicities of SLs **1, 4, 6, 7** and **9**, and their biotransformed products (**10, 14, 15** and **17**) against human cancer cell lines U251 (glia), PC3 (prostate), K562 (leukemia), HCT-15 (colon), MCF7 (breast), and SKLU-1 (lung), were determined, confirming that the presence of Michael acceptor is an important feature for the bioactivity.

Keywords: biotransformations, sesquiterpene lactones, germacrolide, filamentous fungi, cytotoxicities

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/cbdv.201700211

This article is protected by copyright. All rights reserved.

Introduction

There is an increasing body of information about the use of biocatalysis for selective transformations of synthetic and natural products. The principal advantages of the biocatalytic processes are their mild reaction conditions, environmental safety, and high selectivity [1]. Special attention has been paid to filamentous fungi because they catalyze *situ*-, *regio*- and *stereo*-selective reactions [2]. Sesquiterpene lactones (SLs) constitute a group of compounds mainly isolated from species of the family Asteraceae. SLs possess a wide spectrum of bioactivity [3] such as anti-inflammatory properties [4-7] and cytotoxicity against tumor cell lines [7-10]. It is widely accepted that thiol groups such as cysteine residues in proteins, as well as the free intracellular glutathione (GSH), serve as the major targets for SLs [11,12]. The interaction between SLs and protein thiol groups or GSH leads to reduction of enzymatic activity, or causes the disruption of GSH metabolism and the intracellular cell redox balance [13,14]

The main types of reported biotransformations of SLs with various filamentous fungi include hydrogenations, hydroxylations, acylations, methoxylations, and epoxidations, among others [15-22]. Particularly, the biotransformations of the antimalarial sesquiterpene lactone artemisinin or related compounds have been studied [23-27].

Thus, with the aim of exploring the bioreactivity and bioactivity of several SLs, we carried out the transformations of arglanin (**1**) [28-30], 11,13- dehydroeriolin (**2**) [31, 32], budlein B (**3**) [33,34], ludovicin A (**4**) [28], santamarin (**5**) [28], epoxysantamarin (**6**) [28], parthenolide (**7**) [35], sphaerocephalin (**8**) [36] and deacetylconfertiflorin (**9**) [37] by eight filamentous fungi previously used by our group [38]. The biotransformations afforded the products **10-17**, which were previously characterized as natural products. Therefore, these derivatizations imitate their natural biosynthesis. The cytotoxicities of all the available compounds against human cancer cell lines U251 (glia), PC-3 (prostate), K562 (leukemia), HCT-15 (colon), MCF7 (breast), and SKLU-1 (lung) were also evaluated.

Results and Discussion

The biotransformation of arglanin (**1**) [28] with *Rhizopus nigricans*, *Beauveria bassiana*, *Curvularia lunata*, *Aspergillus niger*, and *Cunninghamella blakesleeana* afforded vulgarin (**10**) [39] as the major product (62, 72, 75, 78, 77% yied, respectively), while with *Mucor miehei*, *Rhizopus oligosporus* and *Fusarium moliniforme*, the biotransformation proceeded in relative low yield (< 10% by NMR analysis of the mixture).

The ^1H NMR spectrum of vulgarin **10** did not show the two downfield doublets at δ_{H} 6.15 (d) and 5.48 (d) derived to the exocyclic vinylic hydrogens in **1**. Instead, a new methyl signal at δ_{H} 1.27 (d, $J = 7$ Hz) corresponding to CH_3 -13 (δ_{H} 1.27) and a signal at δ_{H} 2.35 (dq, $J = 13.0, 7.0$ Hz) for H-11 appeared. The orientation of the methyl group at C-11 was established as α - by the observed NOESY correlations between H-6 β (δ_{H} 4.17), H₃-15 β (δ_{H} 1.57), H₃-14 β (δ_{H} 1.22) with H-11 β (δ_{H} 2.35). The HMBC and HSQC correlations confirmed the structure of vulgarin (**10**) [39] for this compound.

The stereoselective hydrogenation of the olefin was the transformation observed for 11,13-dehydroeriolin (**2**) with *A. niger*, *C. blakesleeana*, *B. bassiana* and *F. moliniforme*, affording eriolin (**11**) [31, 40]. The configuration at C-11 was deduced from the observed NOESY correlation of the β -oriented H-8 (δ_{H} 4.17) and H-6 (δ_{H} 2.16) with H-11 (δ_{H} 2.57), as well as the correlation between H-7 α (δ_{H} 1.93) with CH_3 -13 (δ_{H} 1.27), establishing the 11*R*- configuration [40].

Incubations of budlein B (**3**) [33, 34] with *C. lunata* and *A. niger* in medium B (see Experimental), afforded *allo*-schkuhriolide (**12**) [34]. The formation of **13** can be rationalized via an oxidation of the allylic alcohol of C-14, affording the aldehyde, followed by isomerization of the C1-C10 double bond.


The biotransformation of ludovicin A (**4**) [28] with *C. lunata* in medium B produced tuberiferin (**13**, 31%) [41] and ludovicin B (**14**, 52%) [30]. Compound **13** had the molecular formula $\text{C}_{15}\text{H}_{18}\text{O}_3$ (M^+ , m/z 248), as determined by EIMS. Its IR spectrum showed bands for a γ -lactone (1768 cm^{-1}) and for an α,β -unsaturated ketone (1675 cm^{-1}). The ^1H NMR spectrum revealed the presence of hydrogens representative of an exocyclic methylene conjugated with the γ -lactone at δ_{H} 6.12 and 5.43 (d, $J = 3$ Hz for H-13a y H-13b), and the vinylic hydrogens of an α,β -unsaturated ketone at δ_{H} 6.71 and δ_{H} 5.91 (d, $J = 9$ Hz each) corresponding to H-1 and H-2, respectively. The signal at δ_{H} 2.62 (dq, $J = 7$ Hz) was assigned to H-4, based on the COSY correlation of H-4 with H-5 (δ_{H} 2.1, dd, $J = 7, 10$ Hz) and H-15 (δ_{H} 1.4, d, $J = 7$ Hz, 3H). The β -orientation of H-4 was determined by its NOESY correlation with H-6 and H₃-14. The ^1H and ^{13}C NMR data and physical properties were in agreement for those of tuberiferin (**13**), previously isolated from *Sonchus tuberifer* [41]. Compound **14** was previously characterized from *A. ludoviciana* ssp *mexicana* [30]. The formation of **13** and **14** from **4** could be explained by the regioselective opening of the oxirane, followed by removal of a proton to generate the allylic alcohol **14**; semipinacolic-type rearrangement (or a 1,3-isomerization of the allylic proton from C-3 to C-15, followed by keto-enol tautomerization) would produce the ketone, and a dehydration reaction would afford the α,β -unsaturated ketone **13**.

Santamarin (**6**) [28] was transformed by the different fungi tested to 3 α -hydroxyreynosin (**15**) in relatively low yield, but epoxysantamarin (**6**) was relatively efficiently transformed by *C. lunata* and *A. niger* (see Experimental).

Screening-scale experiments showed that eight microorganisms used in this study were capable of converting parthenolide (**7**) into compound **16** [35]. However, with *B. bassiana* (medium A) and *C. lunata* (medium B), 1,10-epoxy-11 β H,13-dihydroparthenolide (**17**) [42] was obtained. The HRFABMS established a molecular formula of C₁₅H₂₃O₄ [M+H]⁺, 267.1595, calcd. 267.1597, and the ¹H NMR spectrum revealed a signal at δ_H 1.28 (d, J = 7.0 Hz, 3H), which corresponded to CH₃-13, indicative of the hydrogenation of the exocyclic olefin. The presence of an epoxide at C-1 and C-10 in **17** was confirmed on the basis of ¹³C NMR, HMQC and HMBC experiments. Particularly, H-5 (δ_H 2.82, d, J = 10 Hz) and H-1 (δ_H 2.82, dd; J = 10, 2 Hz) appeared at the same chemical shift, and the corresponding carbons appeared at δ_C 84.3 and δ_C 63.8, respectively. Furthermore, the HMBC correlation of C-5 with H-3 β (δ_H 2.16), H-7 α (δ_H 2.28) and H₃-15 (δ_H 1.47), C-1 (δ_C 63.8) with H-9 β (δ_H 2.25) H-2 α , H-3 α and H₃-14, confirmed structure **17**.

Sphaerocephalin (**8**) [36] and deacetylconfertiflorin (**9**) [37] were not biotransformed by any of the eight fungi in the tested conditions (using medium A).

The cytotoxic activities of the natural compounds used as starting material (**1**, **4**, **6**, **7** and **9**), and the biotransformation products (**10**, **14**, **15**, and **17**) were evaluated against selected human cancer cell lines: U251 (glia), PC-3 (prostate), K562 (leukemia), HCT-15 (colon), MCF7 (breast), SKLU-1 (lung), following standard procedures, and the results are summarized in Table 1 (some bioactivities were not determined due to the paucity of available material). All the compounds displayed activity (as determined by IC₅₀ values below 100 μ M), with lactones **10** and **17** being less active. It was confirmed that the cytotoxicities of sesquiterpene lactones reside chiefly on the presence of Michael acceptor groups, although the presence of additional polar groups and stereoelectronic considerations are also important. Parthenolide (**7**) was the most active compound, but displayed limited selectivity.



Scheme 1. Biotransformations of sesquiterpene lactones **1** – **6** with filamentous fungi. *a*: *R. nigricans*, *b*: *B. bassiana*, *c*: *C. lunata*, *d*: *A. niger*, *e*: *C. blakesleeana*, *f*: *M. miehei*, *g*: *R. oligosporus*, *h*: *F. moliniforme*.

Table. Table. Cytotoxicity IC₅₀ values (μM) of sesquiterpene lactones against selected cancer cell lines.

Compound	U251	PC-3	K562	HCT-15	MCF7	SKLU-1
	(glia)	(prostate)	(leukemia)	(colon)	(breast)	(lung)
1	10.25±0.15	10.98±0.8	12.18±0.64	10.98±0.54	10.05±0.37	nd
4	35.73±0.35	39.76±0.6	36.43±0.4	nd	38.66±0.83	nd
6	26.47±0.5	32.8±0.5	nd	nd	nd	nd
7	5.34±0.12	6.4±0.2	nd	nd	1.32±0.45	7.09±0.9
9	26.57±0.28	24.78±0.9	22.27±0.87	22.14±0.76	20.1±1.9	19.89±0.9
10	65.70±0.52	75.64±0.37	73.29±0.12	84.41±0.27	nd	nd
14	nd	50.09±0.6	36.58±0.3	nd	nd	nd
15	23.12±0.4	27.98±1.49	21.28±0.12	nd	nd	nd
17	72.77±0.81	78.14±1.1	76.97±3.7	nd	nd	nd
Helenalin	0.32±0.02	nd	nd	nd	0.19±0.03	0.21±0.02

The sesquiterpene lactone helenalin was taken as reference [43]. Nd: not determined, due to the paucity of available material.

Conclusions

The hydrogenation of the $\Delta^{11(13)}$ double bond was the common process in microbial transformation of sesquiterpene lactones **1**, **2**, **4** and **7** by the filamentous fungi used. The reduction of the $\Delta^{11(13)}$ olefin appears to be dependent on the compound involved, the concentration used, and the fungi assayed. The fungal transformation of the tested lactones are in accordance to the commonly accepted biogenetic routes, since the obtained products have been found also as natural products. The eudesmanolides (**1**, **4**, **5**, **6**) appear to be more reactive toward biotransformations in comparison with germacrolides (**2**, **3** and **7**). This is the first report on the biotransformations of compounds **1** – **6**, and it is interesting to note that two of the nine assayed compounds (sphaerocephalin **8** and deacetylconfertiflorin **9**) were not transformed by the tested fungi. The presence of the α -methylene- γ -lactone is responsible in most cases for the cytotoxicities of these substances, and they displayed limited bioselectivities.

Experimental Section

General

Melting points were determined on a Fischer-Jones apparatus. Optical Rotation were measured on a Perkin-Elmer 341 polarimeter. IR: Nicolet Magna FT-IR 750 spectrometer. ¹H and ¹³C NMR spectra were taken on a Varian Unity-plus 500 (at 500/125 MHz) instrument. EI-MS: Jeol JMS-AX505HA mass spectrometer and Jeol JMS-SX 102 A) for HREIMS. TLC spots were revealed by spraying with ceric ammonium sulfate, followed by heating. Vacuum Column Chromatographies

(VCC) were done following the reported procedures [44]. Column Chromatography (CC) were performed using silica gel 70-230 and TLC using silica gel 60F₂₅₄ (Merck) plates.

Fungi, Media and Culture Conditions

Rhizopus nigricans (ATCC 6227b), *Beauveria bassiana* (ATCC 13144), *Curvularia lunata* (ATCC 13432), *Aspergillus niger* (ATCC 16404), *Cunninghamella blakesleeana* (ATCC 8688a), *Mucor miehei* (ATCC 16457), *Rhizopus oligosporus* (ATCC 22959), and *Fusarium moliniforme* (ATCC 102091) were obtained from Instituto de Biotecnología, UNAM, Mexico, maintained on potato dextrose agar (PDA), and stored at 4 °C. The medium A for *R. nigricans*, *B. bassiana*, *A. niger*, *C. blakesleeana*, *M. miehei*, *R. oligosporus* and *F. moliniforme* were prepared by mixing the following ingredients in distilled H₂O (1 L): peptone (1 g), yeast extract (1 g), beef extract (1 g) and glucose (5 g). The pH was adjusted to pH 7 before autoclaving. The medium B for *A. niger*, *C. blakesleeana* and *C. lunata* was prepared by mixing glucose (10 g), glycerol (10 g), peptone (5 g), yeast extract (5 g), KH₂PO₄ (5 g) and NaCl (5 g). For, the pH was adjusted to 7 before autoclaving.

Incubation Experiments, Recovery and Purification of Products

Eight fungi, *R. nigricans*, *B. bassiana*, *C. lunata*, *A. niger*, *C. blakesleeana*, *M. miehei*, *R. oligosporus*, *F. moliniforme*, were screened for their capabilities to metabolize compounds **1 – 9** at analytical scale (10-15 mg), and according with these results, experiments were carried out on a preparative scale (150-220 mg), following the same experimental processes [38]. Erlenmeyer cell culture flasks (250 mL) containing 125 mL of medium A or medium B were inoculated with a dense suspension (2 mL) of the corresponding fungi. Incubation was maintained at 25°C with gyratory shaking (125 rpm) for 14 days after which the substrates (2-4 mL) in acetone were added. These biotransformation experiments were monitored by TLC, including two controls, “culture control” and “substrate control”, for determining that the isolated products are not secondary metabolites from the fungi, and that the culture media have not done any transformation on the substrate.

Cultures were filtered and pooled, and cells were washed thoroughly with water, the liquid was saturated with NaCl, and extracted with CH₂Cl₂. The organic extracts were dried with Na₂SO₄ and concentrated under reduced pressure. The obtained residue was chromatographed by VCC or CC using gradient elution system of *n*-hexane-EtOAc. Representative experimental procedures are described below.

To 72 h of growth of *C. blakesleeana* in medium A, arglanine (**1**) (210.9 mg) was dissolved in acetone (10 mL) and distributed in 13 Erlenmeyer cell culture flasks. After 14 days of incubation and monitoring the reaction by TLC, the crude brownish residue (193.4 mg) was purified by VCC and preparative TLC. This procedure afforded 162.2 mg (77%) of vulgarin (**10**): mp. 175-177 °C. $[\alpha]_D^{25} = +31.58$ ($c = 9.5 \times 10^{-3}$, CHCl₃). IR ν_{max} (CHCl₃) 3571, 2977, 2937, 1789, 1683, cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 6.61 (1H, d, J = 11.0 Hz, H-3), 5.90 (1H, d, J = 11.0 Hz, H-2), 4.17 (1H, dd, J = 11.5, 10.5 Hz, H-6), 2.44 (1H, d, J = 11.5 Hz, H-5), 2.35 (1H, dq, J = 12.0, 7.0 Hz, H-11), 2.05 (1H, ddd, J = 12.0, 3.0, 3.0 Hz, H-9 β), 2.01 (1H, dddd, J = 13.0, 12.0, 3.0, 3.0 Hz, H-8), 1.73 (1H, m, H-7), 1.58 (1H, m, H-7), 1.56 (3H, s, CH₃-15), 1.51 (1H, m, H-9 α), 1.27 (3H, d, J = 7 Hz, CH₃-13), 1.22 (3H, s, CH₃-14). ¹³C NMR (125 MHz, CDCl₃): 205.6 (C-1), 151.7 (C-2), 170.1 (C-3), 70.1 (C-4), 54.6 (C-5), 79.6 (C-6), 52.4 (C-7), 22.7 (C-8), 34.2 (C-9), 46.2 (C-10), 40.5 (C-11), 179.9 (C-12), 12.5 (C-13), 23.8 (C-14), 19.8 (C-15). EM (IE) m/z : 264 [M⁺] (15.8), 231 (12.3), 203 (19.2), 132 (36.3), 133 (100), 121 (10.9), 98 (31.5), 93 (28.1), 55 (15.0).

Biotransformation of 11,13-Dehydroeriolin (**2**) with *A. niger*

11,13-Dehydroeriolin (**2**, 200 mg), dissolved in 10 mL of Me₂CO, was distributed among 20 flask containing 125 mL of medium A. The crude product obtained in each case was purified by VCC using *n*-hexane and increasing quantities of EtOAc (5-100%), this afforded 122.2 mg (61.12%) of eriolin (**11**) [30], mp 234-236°C [CH₂Cl₂/*i*-Pr₂O]. Similar conditions and procedures were followed for the biotransformation of **2** (200 mg) with *F. moliniforme*, to obtain **11** (137.2 mg, 68.6%), while with *B. bassiana* (70%) and *C. blakesleeana* (64%), **11** was obtained in ca. 5% yield.

Biotransformation of Budlein B (**3**) with *C. lunata*

To 72 h of growth of *C. lunata* in medium B, budlein B (**3**, 189.7 mg) was dissolved in acetone (10 mL) and distributed in 15 Erlenmeyer cell culture flasks. After 14 days of incubation, the obtained organic residue (150.4 mg) was purified by VCC and preparative TLC, obtaining **3** (142.3 mg, 75%) and **12** (41.7 mg, 22%). Similar conditions and procedures were followed for the biotransformation of **3** (150 mg) with *A. niger*, to obtain **12** (87.2 mg, 58.1%) [34].

Biotransformation of Ludovicin A (**4**) with *C. lunata*

Ludovicin A (**4**, 202.4 mg), dissolved in 10 mL of Me₂CO, was distributed among 20 Erlenmeyer cell culture flasks containing 125 mL of medium B (pH 7). The biotransformation was stopped after 14 days. The crude residue (188.4 mg) was purified by VCC using *n*-hexane and increasing quantities of EtOAc, yielding recovered **4** (24.3 mg, 12%), **13** (62.7 mg, 31%) and **14** (105.3 mg,

52%) [30]. Tuberiferin (**13**): white solid (62.7 mg, 31%), mp. 145-147 °C. IR ν_{\max} (CHCl₃): 1768, 1675, 1457 cm⁻¹; ¹H NMR (300 MHz, CDCl₃), δ 6.71 (1H, d, J = 9 Hz, H-1), 6.12 (1H, d, J = 3 Hz, H-13a), 5.91 (1H, d, J = 9 Hz, H-2), 5.43 (1H, d, J = 3 Hz, H-13b), 2.62 (1H, dc, J = 7, 4 Hz, H-4), 2.1 (1H, dd, J = 10, 7 Hz, H-5), 3.98 (1H, t, J = 10 Hz, H-6), 2.58 (1H, m, H-7), 2.13 (1H, m, H-8 α), 1.79 (1H, ddd, J = 10, 3 Hz, H-8 β), 1.75 (1H, m, H-9 β), 1.68 (1H, dd, J = 10, 3 Hz, H-9 α), 1.40 (3H, d, J = 4 Hz, H-15), 1.17 (3H, s, H-14). ¹³C NMR (75 MHz, CDCl₃), δ 157.8 (C-1), 126.8 (C-2), 200.4 (C-3), 42.1 (C-4), 52.3 (C-5), 82.0 (C-6), 50.2 (C-7), 21.2 (C-8), 37.2 (C-9), 38.5 (C-10), 138.3 (C-11), 170.1 (C-12), 117.5 (C-13), 19.3 (C-14), 14.8 (C-15). EM (IE) m/z : 248 [M⁺, 1.2], 232 (2.1), 218 (2.1), 189 (48.0), 148 (32.5), 108 (18.0), 93 (31.0), 76 (76.0), 51 (26.0), 40 (15.0).

Biotransformation of Epoxysantamarin (6) with C. lunata

Compound **6** (100.2 mg) was dissolved in acetone (10 mL) and distributed in 15 Erlenmeyer cell culture flasks containing 2 mL of *A. niger* (48 h of growth) in medium A. After 6 days of incubation, the starting material was consumed and the crude residue was purified by CCV and preparative TLC, recovering **6** (17.8 mg, 17.8 %) and **15** (53.4 mg, 53.3%) [28].

Biotransformation of parthenolide (7) with B. bassiana

Substrate **7** (200 mg) was dissolved in Me₂CO (10 mL) and distributed among 20 Erlenmeyer cell culture flasks and incubated for 14 days. After this time, the cultures were filtered and pooled; the cells were washed thoroughly with water and the liquid was saturated with NaCl and extracted twice with CH₂Cl₂. Extracts were pooled, dried with anhydrous Na₂SO₄, the organic solvent was removed, and the residue was chromatographed on a silica gel column, affording **7** (24.1 mg, 12.1%), **16** (83.9 mg, 42%) and **17** (19.8 mg, 9.9%). 11 β H,13-Dihydroparthenolide (**16**): mp. 134-36 °C. IR ν_{\max} (CHCl₃): 2980, 2932, 1774 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): 5.15 (1H, dd, J = 12.0, 2.3, H-1), 3.80 (1H, t, J = 10.0, 8.4 Hz, H-6), 2.69 (1H, d, J = 10.0, H-5), 2.37 (1H, dddd, J = 13.0, 13.0, 12.0, 5.0 Hz, H-2 β), 2.28 (1H, m, H-7), 2.28 (1H, m, H-8 β), 2.27 (1H, dq, J = 10.3, 6.8, H-11 β), 2.25 (1H, m, H-9 β), 2.11 (1H, dddd, J = 13.0, 13.0, 6.0, 2.3 Hz, H-2 α), 2.16 (1H, m, H-3 β), 1.80 (1H, m, H-8 α), 1.80 (1H, m, H-9 α), 1.68 (3H, s, CH₃-14), 1.27 (3H, s, CH₃-15), 1.25 (1H, d, J = 6.8, CH₃-13), 1.21 (1H, dt, J = 13.0, 5.6 Hz, H-3 α). ¹³C NMR (75 MHz, CDCl₃): 125.2 (C-1), 24.7 (C-2), 36.7 (C-3), 61.4 (C-4), 66.4 (C-5), 82.2 (C-6), 51.9 (C-7), 29.8 (C-8), 41.2 (C-9), 134.4 (C-10), 42.5 (C-11), 177.3 (C-12), 13.3 (C-13), 16.9 (C-14), 17.1 (C-15).

1,10-Epoxy-11 β H,13-dihydroparthenolide (**17**): mp. 146-148°C. IR ν 3686, 2972, 2932, 1780, 1602 cm⁻¹. The HRFABMS established a molecular formula of C₁₅H₂₃O₄ [M+H]⁺, 267.1595, Calcd. 267.1597]. ¹H NMR (500 MHz, δ CDCl₃): 3.80 (1H, t, J = 10.0, 8.4 Hz, H-6), 2.83 (1H, d, J = 10.0, H-5), 2.37 (1H, dd, J = 11.9 y 2.3, H-1), 2.37 (1H, dddd, J = 13.0, 13.0, 12.0, 5.0 Hz, H-2 β), 2.28 (1H, m, H-7), 2.28 (1H, m, H-8 β), 2.27 (1H, dq, J = 10.3, 6.8, H-11 β), 2.25 (1H, m, H-9 β), 2.16 (1H, m, H-3 β), 2.11 (1H, dddd, J = 13.0, 13.0, 6.0, 2.3 Hz, H-2 α), 1.80 (1H, m, H-8 α), 1.80 (1H, m, H-9 α),

1.68 (3H, s, CH₃-14), 1.27 (3H, s, CH₃-15) 1.25 (1H, d, J = 6.8, CH₃-13), 1.21 (1H, dt, J= 13.0, 5.6 Hz, H-3 α). ¹³C NMR (CDCl₃, 125 MHz): 63.8 (C-1), 23.8 (C-2), 35.2 (C-3), 60.5 (C-4), 64.5 (C-5), 81.4 (C-6), 51.8 (C-7), 25.5 (C-8), 40.1 (C-9), 60.4 (C-10), 42.7 (C-11), 176.8 (C-12), 12.9 (C-13), 16.9 (C-14), 17.4 (C-15).

Cytotoxicity bioassays

Human tumor cell lines were supplied by National Cancer Institute (NCI), USA. The cytotoxicity of the tumors cells with the test compounds was determined using the protein-binding dye sulforhodamine B (SRB) in microculture assay to measure cell growth. The cell lines were cultured in RPM-1640 (Sigma Chemical Co Ltd. St. Louis, MO, USA), supplemented with 10% fetal bovine serum, 2 μ M L-glutamine, 100 IU/mL penicillin G, 100 μ g/mL streptomycin sulfate and 0.25 μ g/mL amphotericin B (Gibco). They were maintained at 37 °C in a 5% CO₂ atmosphere with 95% humidity. For the assay, 5 x 10⁴ cell/mL and 100 μ L/ well of these cells suspensions were seeded in 96-well microtiter plates, and incubated to allow the cell attachment. After 24 h, 100 μ L the test compounds and positive substances were added to each well, and after 48 h adherent cell cultures were fixed *in situ* by adding 50 μ L of cold 50% (wt/vol) trichloroacetic acid (TCA) and incubated for 60 min at 4°C. The supernatant was discarded and the plates were washed three times with water and air-dried. Cultured fixed with TCA were stained for 30 min with 100 μ L of 4% SRB solution. Protein bound dye was extracted with 10 μ M un buffer tris base and the optical densities were read on an Ultra Microplate Reader (Elx 808, BIO-TBK Instruments, Inc.) with a test wavelength of 515 nm. Results were expressed as inhibitory concentration 50 (IC₅₀) values, they were calculated according to the protocol of Monks [45], where a dose-response curve was plotted for each compound, and the concentration giving 50% inhibition (IC₅₀) was estimated from linear regression equations. Helenanin (IC₅₀= 0.32 \pm 0.02 μ M against U251) was used as positive control.

Supplementary Material

Supporting information for this article is available on the www under <http://dx.doi.org/10.1002/MS-number>.

Acknowledgements

This work was taken in part from the PhD thesis of Arturo Cano Flores. submitted to Programa de Maestría y Doctorado en Ciencias Química de la Universidad Nacional Autónoma de México. The authors thank Rocío Patiño, Ángeles Peña, María Isabel Chávez, Beatriz Quiroz, María Teresa Ramírez-Apan, Luis Velasco, Javier Pérez, and Antonio Nieto (Instituto de Química, UNAM), for technical assistance. A. C.-F. thanks Programa de Apoyo para la Superación del Personal

Académico, Dirección General de Asuntos del Personal Académico, UNAM. Financial support from, UNAM, DGAPA PAPIIT IN216012, and Carrera de Biología, FES-Zaragoza, UNAM, is gratefully acknowledged. This paper is dedicated to the memory of Dr. Jesús Romo (1922-1977) and Dr. Xorge A. Domínguez (1926-1992).

References

- [1] H. L. Holland, K. H. Weber, 'Enzymatic hydroxylation reactions', *Curr. Opin. Biotechnol.* **2000**, *11*, 547-553.
- [2] L. R. Lehman, J.D. Stewart, 'Filamentous fungi: potentially useful catalyst for the biohydroxylations of non-activated carbon centers', *Curr. Org. Chem.* **2001**, *5*, 439-470.
- [3] A. K. Picman, 'Biological activities of sesquiterpene lactones', *Biochem. Syst. Ecol.* **1986**, *14*, 255-281.
- [4] J. Y. Cho, K. U. Baik, J. H. Jung, M. H. Park, 'In vitro anti-inflammatory effects of cynaropicrin, a sesquiterpene lactone, from *Saussurea lappa*', *Eur. J. Pharmacol.* **2000**, *398*, 399-407.
- [5] A. J. García-Piñeres, V. Castro, G. Mora, T. J. Schmidt, E. Strunck, H. L. Pahl, I. Merfort, 'Cysteine 38 in p65/NF- κ B plays a crucial role in DNA binding inhibition by sesquiterpene lactones', *J. Biol. Chem.* **2001**, *276*, 39713-39720.
- [6] K. Schorr, A. J. García-Piñeres, B. Siedle, I. Merfort, F.B. da Costa, 'Guaianolides from *Viguiera gardneri* inhibit the transcription factor NF- κ B', *Phytochemistry* **2002**, *60*, 733-740.
- [7] I. Merfort, 'Perspectives on sesquiterpene lactones in inflammation and cancer', *Curr. Drug Targets* **2011**, *12*, 1560-1573.
- [8] K. H. Lee, E. S. Huang, C. Piantadosi, J. S. Pagano, T. A. Geissman, 'Cytotoxicity of Sesquiterpene Lactones', *Cancer Res.* **1971**, *31*, 1649-1654.
- [9] S. Zhang, Y-K. Won, Ch-N. Ong, H-M. Shen, 'Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms', *Curr. Med. Chem.* **2005**, *5*, 239-249.
- [10] T. J. Schmidt, Structure-activity relationships of sesquiterpene lactones, in: Atta-ur-Rahman (Ed.), in "Studies in Natural Products Chemistry", Elsevier, Amsterdam, 2006, p. 309.
- [11] S. Zhang, C. N. Ong, H. M. Shen, 'Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells', *Cancer Lett.* **2004**, *208*, 143-153.
- [12] T. J. Schmidt, 'Toxic activities of sesquiterpene lactones; structural and biochemical aspects', *Curr. Org. Chem.* **1999**, *3*, 577-605.
- [13] S. M. Kupchan, M. A. Eakin, A. M. Thomas, 'Tumor inhibitors. 69. Structure-cytotoxicity relationships among the sesquiterpene lactones', *J. Med. Chem.* **1971**, *12*, 1147-1152.
- [14] T. J. Schmidt, 'Helenanolide type sesquiterpene lactones. Part 5: The role of glutathione addition under physiological conditions', *Bioorg. Med. Chem.* **1997**, *5*, 645-653.
- [15] Atta-ur-Rahman, M. I. Choudhary, A. Ata, M. Alam, A. Farooq, S. Perveen, M. S. Shekhani, 'Microbial transformation of 7 α -hydroxyfrullanolida', *J. Nat. Prod.* **1994**, *57*, 1251-1255.
- [16] A. F. Barrero, J. E. Oltra, D. S. Raslan, D. A. Saúde, 'Microbial transformation of sesquiterpene lactones by the fungi *Cunninghamella echinulata* and *Rhizopus oryzae*', *J. Nat. Prod.* **1999**, *62*, 726-729.
- [17] A. M. Galal, 'Microbial transformation of Pyrethrosin', *J. Nat. Prod.* **2001**, *64*, 1098-1099.
- [18] G. N. Krishna Kumari, S. Masilamani, G. S. Aravind, 'Microbial transformation of zaluzanin-D', *Phytochemistry* **2003**, *62*, 1101-1104.
- [19] X-Ch. Ma, J. Zheng, D-A. Guo, 'Microbial transformation of dehydrocostulactone and costunolide by *Mucor polymorphosporus* and *Aspergillus candidus*', *Enzyme Microb. Technol.* **2007**, *40*, 1013-1019.
- [20] B. A. Rocha, M. T. Pupo, G.A. Antonucci, S. V. Sampaio, R. de Melo Alves Paiva, S. Said, L. Gobbo-Neto, F. B. DaCosta, 'Microbial transformation of the sesquiterpene lactone tagitinin C by the fungus *Aspergillus terreus*', *J. Ind. Microbiol. Biotechnol.* **2012**, *39*, 1719-1724.
- [21] D. Wang, L. Yang, H. Guan, Y-N. Chen, W-Z. Xu, S. You, 'Stereoselective hydrogenation on the exocyclic and conjugated double bond of sesquiterpene lactones by *Aspergillus versicolor* D-1', *J. Asian Nat. Prod. Res.* **2009**, *11*, 991-996.

- [22] A. García-Granados, M. C. Gutiérrez, A. Parra, F. Rivas, 'Chemical-microbiological synthesis of cryptomeridiol derivatives by *Gliocladium roseum*: semisynthesis of 11-hydroxyeudesmanolide', *J. Nat. Prod.* **2002**, *65*, 1011-1015.
- [23] I-S. Lee, H. N El-Sohly, E. M. Croom, C. D. Hufford, 'Microbial Metabolism Studies of the Antimalarial Sesquiterpene Artemisinin', *J. Nat. Prod.* **1989**, *52*, 337-341.
- [24] S. A. Elmarakby, F. S. El-Feraly, H. N. Elsohly, E. M. Croom, C. D. Hufford, 'Microbial Transformation Studies on Arteannuin B', *J. Nat. Prod.* **1987**, *50*, 903-909.
- [25] K. Y. Orabi, A. M. Galal, A-R. S. Ibrahim, F.S. El-Feraly, S. I. Khalifa, H .N. El-Sohly, 'Microbial metabolism of artemisitene', *Phytochemistry* **1999**, *51*, 257-261.
- [26] J. Zhan, H. Guo, J. Dai, Y. Zhang, D. Guo, 'Microbial transformations of artemisinin by *Cunninghamella echinulata* and *Aspergillus niger*', *Tetrahedron Lett.* **2002**, *45*, 4519-4521.
- [27] J-H. Liu, Y-G. Chen, B-Y. Yu, Y-J. Chen, 'A novel ketone derivative of artemisinin biotransformed by *Streptomyces griseus* ATCC 13273', *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1909-1912.
- [28] A. Ruiz-Cancino, A. E. Cano, G. Delgado, 'Sesquiterpene lactones and flavonoids from *Artemisia ludoviciana* ssp. *Mexicana*', *Phytochemistry* **1993**, *33*, 1113-1115.
- [29] S. Matsueda, T. A. Geissman, 'Sesquiterpene lactones of Artemisia species III. Arglanine from *Artemisia douglasiana* Bess.', *Tetrahedron Lett.* **1967**, *21*, 2013-2015.
- [30] R. Mata, G. Delgado, A. Romo de Vivar, 'Sesquiterpene lactones of *Artemisia mexicana* var. *angustifolia*', *Phytochemistry* **1984**, *23*, 1665-1668.
- [31] A. Romo de Vivar, A. L. Pérez, C. León, G. Delgado, '11,13-Dehydroeriolin, Schkuhrioidin and Schkuhriolide, Germacranolides from *Schkuhria* species', *Phytochemistry* **1983**, *21*, 2905-2908.
- [32] A. León, B. Reyes, M. I. Chávez, R. A. Toscano, G. Delgado, 'Sesquiterpene lactones, acyl phenyl propanoids and other constituents from *Schkuhria pinnata* var. *wislizeni*. Antioxidant evaluation', *J. Mex. Chem. Soc.* **2009**, *53*, 193-200.
- [33] A. Romo de Vivar, E. A. Bratoeff, E. Ontiveros, D. C. Lankin, N. S. Bhacca, 'Vigulenin, a germacranolide from *Viguiera linearis*', *Phytochemistry* **1980**, *19*, 1795-1799.
- [34] G. Delgado, V. Tejeda, A. Salas, M.I. Chávez, S. Guzmán, A. Bolaños, M. I. Aguilar, V. Navarro, M. L. Villareal, New melampolides from *Schkuhria schkuhrioides*, *J. Nat. Prod.* **1998**, *61*, 1082-1085.
- [35] A. M. Galal, A-R. S. Ibrahim, J. S. Mossa, F. S. El-Feraly, 'Microbial transformation of parthenolide', *Phytochemistry* **1999**, *51*, 761-765.
- [36] A. Ortega, R. Lara, R. Martínez, E. Díaz, 'Sphaerocephalin, a germacrolide isolated from *Viguiera sphaerocephala*', *Phytochemistry* **1980**, *19*, 1545-1546.
- [37] G. Delgado, M. I. Chávez, L. Alvarez, L. 'New Seco-Pseudoguaianolides and Other Terpenoids from a Population of *Ambrosia confertiflora*', *J. Nat. Prod.* **1988**, *51*, 83-87.
- [38] A. Cano, M. T. Ramírez-Apan, G. Delgado, 'Biotransformation of sclareolide by filamentous fungi: cytotoxic evaluations of the derivatives', *J. Braz. Chem. Soc.* **2012**, *22*, 1177-1182.
- [39] T. A. Geissman, A. Ellestad, 'Vulgarin, a sesquiterpene lactone from *Artemisia vulgaris* L.', *J. Org. Chem.* **1962**, *27*, 1855-1859.
- [40] S. J. Torrance, T. A. Geissman, M. R. Chedekel, 'Sesquiterpenolactones, the constituents of *Eriophyllum confertiflorum*', *Phytochemistry* **1969**, *8*, 2381-2392.
- [41] J. B. Bermejo, J. L. Bretón, M. Fajardo, A. G. González, 'Terpenoids from *Sonchus tuberosus* Svent.', *Tetrahedron Lett.* **1967**, *36*, 3475-3476.
- [42] D. E. Wedge, J. C. G. Galindo, F. A. Macías, 'Fungicidal activity of natural and synthetic sesquiterpene lactone analogs', *Phytochemistry* **2000**, *53*, 747-757.
- [43] E. Ríos, A. León, M. I. Chávez, Y. Torres, M. T. Ramírez-Apan, R. A. Toscano, A. E. Bravo-Monzón, F. Espinosa-García, G. Delgado, 'Sesquiterpene lactones from *Mikania micrantha* and *Mikania cordifolia* and their cytotoxic and anti-inflammatory evaluation'. *Fitoterapia* **2014**, *94*, 155-163
- [44] J. C. Coll, B. F. Bowden, 'The Application of Vacuum Liquid Chromatography to the Separation of Terpene Mixtures', *J. Nat. Prod.* **1986**, *49*, 934-936.
- [45] A. Monks, D. Seudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, M. Boyd, *J. Nat. Cancer Inst.* **1991**, *83*, 757-766.